Regeneron Pharmaceuticals (REGN) Interest Expenses (2009 - 2026)

Regeneron Pharmaceuticals has reported Interest Expenses for 18 years, with the latest figure at $11.0 million in Q2 2026.

• On a quarterly basis, Interest Expenses rose 205.56% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $55.4 million, a 51.37% increase from a year earlier, with the FY2025 full-year figure at $43.8 million, down 20.65% from the prior year.
• Interest Expenses was $11.0 million for Q2 2026 at Regeneron Pharmaceuticals, down from $12.9 million in the prior quarter.
• The five-year high for Interest Expenses was $19.3 million in Q3 2025, with the low at $3.6 million in Q2 2025.
• Average Interest Expenses over 5 years is $14.2 million, with a median of $14.3 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Interest Expenses sank 75.68% in 2025, then jumped 205.56% in 2026.
• Over 5 years, Interest Expenses stood at $17.4 million in 2022, then increased by 5.17% to $18.3 million in 2023, then sank by 42.62% to $10.5 million in 2024, then gained by 16.19% to $12.2 million in 2025, then decreased by 9.84% to $11.0 million in 2026.
• The last three Interest Expenses figures came in at $11.0 million (Q2 2026), $12.9 million (Q1 2026), and $12.2 million (Q4 2025), per Business Quant data.